Posted in | News | Renewable Energy | Wind Power

Marubeni Subsidiary Acquires 90% Economic Interest in Shiloh IV Wind Project

EDF Renewable Energy and Marubeni Corporation announced today that a subsidiary of Marubeni acquired a 90 percent economic interest in the 102.5 MW Shiloh IV Wind Project.

The Shiloh IV Wind Project, located in Solano County, California, commenced operations in December 2012 and supplies carbon-free electricity into the CAISO transmission system under a 25-year power purchase agreement with Pacific Gas and Electric. Consisting of 50 REpower MM92 turbines, Shiloh IV generates clean electricity sufficient to supply approximately 40,000 average homes.

EDF Renewable Energy will retain a 10 percent stake in the project. Its affiliate EDF Renewable Services will continue to provide operations and maintenance services. Marubeni will participate in asset management roles working with EDF Renewable Energy in the administration of the project.

“EDF Renewable Energy values this partnership with Marubeni and the opportunity to engage in another successful transaction,” said Raphael Declercq, Director of Divestiture and Portfolio Management. “This sale illustrates our ability to recycle capital to fund future development while staying fully involved in the project. This is an important aspect of our business model that allows us to further our ambition as a world-class renewable project developer.”

“With this investment we recognize the experience and successful track record of EDF Renewable Energy and we look forward to strengthening our relationship. Marubeni is committed to expanding our power generation portfolio in North America and other global markets,” said Toshi Fukumura, President and CEO of New York-based Marubeni Power International, Inc.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.